

# Ensuring bioanalytical compliance of your BA/BE study

Helmut Schütz

**BEBAC**

Consultancy Services for  
Bioequivalence and Bioavailability Studies

1070 Vienna, Austria

[helmut.schuetz@bebac.at](mailto:helmut.schuetz@bebac.at)


# Main Topics

- Method validation (Arlington Conferences I-III and beyond)
- Validation = Suitability for Use?
- Matrix Effects in LC/MS-MS
- Ligand Binding Assays
- Plausibility Review



# Assumptions: General



World 'Reality'



Model 'Data'



Theory 'Truth'

# Assumptions: Bioanalytics

- Assumptions should – possibly – be justified in method development, *e.g.*,
  - Absence of co-eluting compounds (MS-MS < MS < FL < EC < UV)
  - Lack of Matrix Effects (LC/MS-MS, Ligand Binding Assays)

$$MF = \frac{\text{peak response in presence of matrix ions}}{\text{peak response in mobile phase}}$$

Matrix Factor ~1

- Protein-binding (generally only total concentration [free+bound] measured)

# Steps in bioanalytical Validation

- Method Development
- Validation Plan
- Pre-Study Validation
- In-Study Validation

# Validating Methods

- Methods used for quantitative measurement of analytes in any given biological matrix must be

*reliable and reproducible for the intended use...*

- Accuracy
- Precision
- Selectivity
- Sensitivity
- Reproducibility
- Stability
- $AUC_T/AUC_\infty > 80\%$  (LLOQ?)
- 20 % Bias / Precision (BE  $\leftrightarrow$  sparse sampling Population PK)

# Validating Methods

- Level of Regulations
  - Non-clinical studies: GLP
  - Clinical studies:
    - EU (CPMP/EWP/QWP/1401/98): The bio-analytical part of bioequivalence trials should be conducted according to the applicable principles of Good Laboratory Practice (GLP).
    - FDA: non-GLP

# Validating Methods

- Reference standard
  - FDA
    - If possible, identical to the analyte.
    - If not, an established chemical form (free base or acid, salt or ester) of known purity can be used.
  - Types
    - Certified reference standards (e.g., USP compendial standards)
    - Commercially supplied reference standards obtained from a reputable commercial source
    - Other materials of documented purity custom-synthesized by an analytical laboratory or other noncommercial establishment.

# Validating Methods

- Reference standard
  - EU (applying OECD-GLPs)
    - Each [...] item should be appropriately identified (e.g., code, Chemical Abstracts Service Registry Number [CAS number], name, ...).
    - For each study, the identity, including batch number, purity, composition, concentrations, or other characteristics to appropriately define each batch [...] should be known.
    - In cases where the test item is supplied by the sponsor, there should be a mechanism, developed in co-operation between the sponsor and the test facility, to verify the identity of the test item subject to the study.
    - The stability of [...] items under storage [...] conditions should be known for all studies.

# Validating Methods

- Reference standard
  - FDA
    - The source and lot number, expiration date, certificates of analyses when available, and/or internally or externally generated evidence of identity and purity should be furnished for each reference standard.

# Validation Plan

- Written Document describing which steps will be performed in the Validation.
  - Purpose of Validation (e.g., 'Validation of bioanalytical method *X* for the determination of *Y* in human plasma').
  - Reference to established method (working instruction, SOP).
  - If another document exists, already describing the usual steps in validation – cross-reference is enough – otherwise detailed descriptions are necessary.

# Pre-Study Validation

- **Full Validation**

- **Selectivity**

Ability of an analytical method to differentiate and quantify the analyte in the presence of other components in the sample.

- $\geq 6$  sources of blank samples of the appropriate biological matrix should be tested for interference, and selectivity should be ensured at the lower limit of quantification (LLOQ).
    - Potential interfering substances: endogenous matrix components, metabolites, decomposition products, and in the actual study, concomitant medication and other exogenous xenobiotics.
    - Acceptable limit:  $< 20\%$  of response at LLOQ (?)

# Pre-Study Validation

- **Full Validation**

- **Selectivity** (cont.'d)

Matrix Effects in MS-based Assays

- Matrix Factor

$$MF = \frac{\text{peak response in presence of matrix ions}}{\text{peak response in mobile phase}}$$

MF=1: no matrix effects

MF<1: ion suppression

MF>1: ion enhancement *or* analyte loss in the absence of matrix during analysis.

# Pre-Study Validation

- **Full Validation**

- **Selectivity** (cont.'d)

Matrix Effects in MS-based Assays

- Suitability of internal standards (IS) in MS
      - Stable isotope – labeled IS:  
 $^2\text{H}$ ,  $^{15}\text{N}$ ,  $^{18}\text{O}$  at 3-6 positions – different  $m/z$ , but similar extraction and chromatography.  
**Should be used whenever possible!**
      - Structural analog IS
        - Neutral radical (e.g.,  $-\text{CH}_3$ ,  $-\text{C}_2\text{H}_5$ ) preferred
        - Radicals of different polarity/pK less suitable (e.g.,  $-\text{OH}$ ,  $\text{NH}_2$ ) because extraction and/or chromatography will be influenced.
      - Last resort: any other compound of similar polarity...

# Pre-Study Validation

- **Full Validation**

- **Selectivity** (cont.'d)

A MF of ~1 not necessary for a reliable bioanalytical assay. However, a highly variable MF in individual subjects would be a cause for the lack of reproducibility of analysis.

- If no stable isotope – labeled IS is used,
      - to predict the variability of matrix effects in samples from individual subjects, MF should be determined in 6 individual lots of matrix.
        - Variability in matrix factors (measured by CV) should be less than 15 %.
    - If the matrix is rare and hard to obtain, the requirement for assessing variability of MFs in 6 lots can be waived.

# Pre-Study Validation

- **Full Validation (cont.'d)**

- **Precision**

Replicate ( $\geq 5$ ) analysis of known concentrations measured at  $\geq 3$  levels (low, intermediate, high).

- Imprecision (CV%):

- $\leq 15\%$  at each concentration (except at LLOQ, where  $\leq 20\%$  is acceptable).

- Inaccuracy (absolute mean bias - RE%):

- $\leq 15\%$  at each concentration (except at LLOQ, where  $\leq 20\%$  is acceptable).

- Both parameters

- **intra-batch** (within analytical run).


- **inter-batch** (between analytical runs; aka repeatability).

# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Precision** (cont.'d)

In 2006 problems evident if trying to work according to FDA's bioanalytical guideline (2001)...



# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Precision** (cont.'d)

Ligand-binding assays according to Arlington III white-paper:

- Replicate ( $\geq 6$ ) analysis of known concentrations measured at  $\geq 5$  levels in duplicate.
      - Anticipated LLOQ
      - $\sim 3\times$  LLOQ
      - Midrange (geometric mean of LLOQ and ULOQ)
      - High ( $\sim 75\%$  of ULOQ)
      - Anticipated ULOQ

# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Precision** (cont.'d)

Ligand-binding assays according to Arlington III white-paper:

- **Inter-batch** impression (CV%) and inaccuracy (absolute mean bias (RE%):
      - $\leq 20$  % at each concentration (except at LLOQ and ULOQ, where  $\leq 25$  % is acceptable).
      - Target total error (sum of the absolute value of the RE% [accuracy] and precision [%CV%]) should be less than  $\leq \pm 30$  % [ $\leq \pm 40$  % at the LLOQ and ULOQ]). The additional constraint of total error allows for consistency between the criteria for pre-study method validation and in-study batch acceptance.

# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Recovery**

The detector response obtained from an amount of the analyte added to and extracted from the biological matrix, compared to the detector response obtained for the true concentration of the pure authentic standard.

Recovery of the analyte does not need to be 100 %, but the extent of recovery of an analyte and of the internal standard should be consistent, precise, and reproducible.

Measured at low/intermediate/high level.

# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Calibration/Standard Curve**

Same matrix as the samples in the intended study spiked with known concentrations (on basis of the concentration range expected).

Number of standards: function of the anticipated range of analytical values, nature of the analyte/response relationship.


- **Blank sample** (matrix sample processed without internal standard),
    - **Zero sample** (matrix sample processed with internal standard),
    - 6 – 8 non-zero samples covering the expected range, including LLOQ.

# Pre-Study Validation


- **Full Validation** (cont.'d)
  - **Calibration/Standard Curve** (cont.'d)
    - Simplest model that adequately describes the concentration-response relationship should be used (*F*-test, Minimum AIC).
    - Selection of weighting and use of a complex regression equation should be justified (analysis of residuals; *F*-test, Minimum AIC).
    - Response at LLOQ  $\geq 5$  times response of blank.
    - Response at LLOQ: precision  $\leq 20$  %, accuracy  $\pm 20$  % from nominal concentration.
    - Response at other levels: accuracy  $\pm 15$  % from nominal concentration.

# Pre-Study Validation

- **Full Validation** (cont.'d)
  - **Calibration/Standard Curve** (cont.'d)
    - At least four out of six non-zero standards should meet the above criteria, including the LLOQ and the calibration standard at the highest concentration.
    - Excluding individual standard points must not change the model used.




# Case Study



Sum of squared residuals:  
0.194707E+08

Sum of weighted squared residuals:  
473468


S:  
217.593 (df =10)



Sum of squared residuals:  
0.965269E+07

Sum of weighted squared residuals:  
155546

S:  
131.465 (df=9)




Correlation:  
0.9992

Weighted correlation:  
0.9989

AIC:  
160.81407

4 runs:  
++-----++




Correlation:  
0.9995

Weighted correlation:  
0.9996

AIC:  
149.45640


6 runs:  
+++++++




# Case Study

Back-calculated standards (linear, 1/x)			
nominal	Acc [%]	mean	CV [%]
0.102	125.09	122.7	2.77
0.102	120.29		
0.313	94.58	93.4	1.78
0.313	92.23		
1.045	91.95	93.4	2.23
1.045	94.90		
3.107	93.15	92.4	1.09
3.107	91.73		
10.42	93.47	95.6	3.21
10.42	97.81		
31.42	105.19	102.4	3.84
31.42	99.62		

Back-calculated standards (quadr., 1/x)			
nominal	Acc [%]	mean	CV [%]
0.102	109.96	107.3	3.46
0.102	104.70		
0.313	94.76	93.5	1.94
0.313	92.19		
1.045	97.81	99.4	2.28
1.045	101.02		
3.107	100.06	99.3	1.08
3.107	98.54		
10.42	98.31	100.5	3.10
10.42	102.72		
31.42	102.40	100.0	3.47
31.42	97.50		




# Case Study



Sum of squared residuals:  
0.965269E+07

Sum of weighted squared residuals:  
155546


S:  
131.465 (df=9)



Sum of squared residuals:  
0.924405E+10

Sum of weighted squared residuals:  
5751.13

S:  
25.2787 (df =9)




Correlation:  
0.9995

Weighted correlation:  
0.9996

AIC:  
149.45640

6 runs:  
+++++-----



Correlation:  
0.9994

Weighted correlation:  
0.9990

AIC:  
109.88582

6 runs:  
+++++-----




# Case Study


Back-calculated standards (quadr., 1/x)			
nominal	Acc [%]	mean	CV [%]
0.102	109.96	107.3	3.46
0.102	104.70		
0.313	94.76	93.5	1.94
0.313	92.19		
1.045	97.81	99.4	2.28
1.045	101.02		
3.107	100.06	99.3	1.08
3.107	98.54		
10.42	98.31	100.5	3.10
10.42	102.72		
31.42	102.40	100.0	3.47
31.42	97.50		

Back-calculated standards (quadr., 1/x <sup>2</sup> )			
nominal	Acc [%]	mean	CV [%]
0.102	105.60	102.9	3.74
0.102	100.16		
0.313	95.19	93.9	1.99
0.313	92.54		
1.045	100.01	101.7	2.29
1.045	103.31		
3.107	102.52	101.7	1.08
3.107	100.96		
10.42	99.91	102.1	3.06
10.42	104.33		
31.42	101.69	99.3	3.37
31.42	96.95		


# Example (LBA Calibration)




Correlation:  
0.9715  
AIC:  
1.76539




Correlation:  
0.9624  
AIC:  
-9.68461



Correlation:  
0.9910  
AIC:  
-6.47417




Correlation:  
0.9996  
AIC:  
-31.69985




Correlation:  
0.9910  
AIC:  
-6.50533

Example data (monoclonal antibody enzyme-linked immunosorbent assay) from Findlay & Dillard (2007)


# Example (LBA Calibration)



# Example (LBA Calibration)



# Example (LBA Calibration)



$$y = D + \frac{(A - D)}{\left(1 + \left(\frac{x}{C}\right)^B\right)}$$

# LBA Calibration

- **Recommendations for 4-PL model**
  - **Optimal Assay Design for Calibration**
    - $\geq 5$  calibration concentrations (according to Arlington III:  $\geq 6$ ) and not more than 8.
    - Calibrators should be prepared and analyzed in duplicate or triplicate.
    - Concentration progression should be logarithmic, typically of the power of 2 or 3.
    - Midpoint concentration of calibrators should be somewhat greater than  $IC_{50}$ .
    - Anchor concentrations outside the expected validated range should be considered for inclusion to optimize the fit.
    - Suboptimal plate layouts should be avoided.



# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Stability**

Stability of the analytes during sample collection and handling.

- **Three freeze-thaw cycles**

≥3 aliquots at low and high levels stored for 24 hours and thawed at room temperature.

When completely thawed, refrozen for 12 to 24 hours.

This cycle two more times repeated, then analyzed after the third cycle.

If instable: samples should be frozen at -70 °C during another FT-cycle.

# Pre-Study Validation

- **Full Validation** (cont.'d)
  - **Stability** (cont.'d)
    - **Short-Term Storage** (bench top, room temperature)  
Three aliquots of each of the low and high concentrations should be thawed at room temperature and kept at this temperature from 4 to 24 hours (based on the expected duration that samples will be maintained at room temperature in the intended study) and analyzed.

# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Stability** (cont.'d)

- **Long-Term Storage** (frozen at the intended storage temperature) should exceed the time between the date of first sample collection and the date of last sample analysis.

Determined by storing  $\geq 3$  aliquots of low/high levels under the same conditions as the study samples.

Volume should be sufficient for analysis on 3 occasions.

Concentrations of all samples should be compared to the mean of back-calculated values for the standards at the appropriate concentrations from the first day of long-term stability testing.

# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Stability** (cont.'d)

- **Long-Term Storage**

Often not finished when clinical phase already starts (Validation report contains a phrase like: '*long-term stability in progress*'). Not recommended, see

[http://www.emea.europa.eu/pdfs/human/chmptemplates/D80\\_AR\\_Generics\\_Non-Clinical\\_Clinical\\_Guidance.pdf](http://www.emea.europa.eu/pdfs/human/chmptemplates/D80_AR_Generics_Non-Clinical_Clinical_Guidance.pdf)

Brief description of analytical methods used, with emphasis on the performance characteristics of assay validation and quality control. Provide information regarding where the bioanalysis was performed. In addition, it is essential to include the date of the start and finish of the bio-analytical phase to see if the long-term stability data of the pre-study validation is enough. Storage conditions of the samples should be stated.

# Pre-Study Validation

- **Full Validation** (cont.'d)
  - **Stability** (cont.'d)
    - **Stock Solution Stability** of drug and the internal standard should be evaluated at room temperature for  $\geq 6$  hours. If the stock solutions are refrigerated or frozen for the relevant period, the stability should be documented. After completion of the desired storage time, the stability should be tested by comparing the instrument response with that of freshly prepared solutions.

# Pre-Study Validation

- **Full Validation** (cont.'d)

- **Stability** (cont.'d)

- **Post-Preparative Stability**

- Stability of processed samples, including the resident time in the autosampler, should be determined.

- The stability of the drug and the internal standard should be assessed over the anticipated run time for the batch size in validation samples by determining concentrations on the basis of original calibration standards.

# Pre-Study Validation

- **Full Validation** (cont.'d)
  - **Sample dilutions**  
of concentrations above the ULOQ.
    - *E.g.*, ~140 % of ULOQ diluted 1:1.
    - Blank matrix should be used in dilution.
    - Replicate ( $\geq 5$ ) analysis.
      - Imprecision (CV%):  $\leq 15$  %
      - Inaccuracy (absolute mean bias - RE%):  $\leq 15$  %

# Pre-Study Validation

- **Partial Validation** (cont.'d)
  - Method transfers between laboratories (or analysts!).
  - Change in analytical methodology (e.g., change in detection systems).
  - Change in anticoagulant in harvesting biological fluid.
  - Change in matrix within species (e.g., human plasma to human urine).
  - Change in sample processing procedures.

# Pre-Study Validation

- **Partial Validation** (cont.'d)
  - Change in species within matrix (e.g., rat plasma to mouse plasma).
  - Change in relevant concentration range.
  - Changes in instruments and/or software platforms.
  - Limited sample volume (e.g., pediatric study).
  - Rare matrices.
  - Selectivity demonstration of an analyte in the presence of concomitant medications and/or specific metabolites.

# Performing the Validation

- Performance of Validation according to the Validation Plan.
  - Results must comply with limits set in the Validation Plan.
- Report of Results:
  - Method Validation Report;
  - will be referred in the Analytical Protocol of PK/BA/BE-studies.

# In-Study Validation

- Application of Validated Method to Routine Analysis
  - System Suitability (SS)
    - FDA (2001): Based on the analyte and technique, a specific SOP (or sample) should be identified to ensure optimum operation of the system used.
    - Arlington III (2007): As part of qualifying instruments, performance of SS ensures that the system is operating properly at the time of analysis.
      - SS checks are more appropriately used for chromatographic methods to ensure that the system is sufficiently sensitive, specific, and reproducible for the current analytical run.
      - However, the SS tests do not replace the required run acceptance criteria with calibration standards and QC samples.
      - SS tests, when appropriate, are recommended to ensure success, but are not required, nor do they replace the usual run acceptance criteria.

# In-Study Validation

- Study Samples should be analyzed according to the Analytical Protocol.
  - Minimum number of QCs (in multiples of three) should be at least 5 % of the number of unknown samples or six total QCs, whichever is greater.
    - Low / intermediate / high concentration levels
      - At least duplicates at each level.
      - Low: within  $\geq$ LLOQ and  $3 \times$ LLOQ
      - Intermediate: near the center of the calibration range ('center' according to Arlington III white-paper: geometric mean of LLOQ and ULOQ)
      - High: near the ULOQ ( $\geq 75$  % ULOQ)

# In-Study Validation

- Study Analyses (cont.'d)
  - Quality Control Samples (QCs) should be analyzed together with Calibrators and study samples.
    - **Acceptance Criteria for an analytical run**

**QCs**  
85 % – 115 % accuracy for single determinations of QCs; not more than 33 % (two *different* out of six) per run should be out of range.

**Standard Curve**  
85 % – 115 % accuracy for 75 % of standard points, except at LLOQ (80 % – 120 %).  
Values outside this ranges can be discarded, provided they do not change the model established in validation.

# In-Study Validation

- Study Analyses (cont.'d)
  - Samples can be analyzed with a single determination [...] if the assay method has acceptable variability as defined by validation data.
  - For a difficult procedure **with a labile analyte<sup>\*)</sup>** where high precision and accuracy specifications may be difficult to achieve, duplicate or even triplicate analyses can be performed for a better estimate of analyte. <sup>\*) removed in Arlington III</sup>

replication	CV [%]				
0 (single)	20.0%	25.0%	30.0%	40.0%	50.0%
1 (duplicate)	14.1%	17.7%	21.2%	28.3%	35.4%
2 (triplicate)	11.5%	14.4%	17.3%	23.1%	28.9%
3 (quadruplicate)	10.0%	12.5%	15.0%	20.0%	25.0%

# In-Study Validation




- Study Analyses (cont.'d)
  - Acc. to Arlington III WP:
    - Mandatory SOPs (additional to the 'common' ones...):
      - Reintegration (incl. audit trail).
      - Reassay criteria.

# Plausibility Review

- Plausibility Review of analytical data
  - If ever possible, plan a blinded Plausibility Review of analytical data by an independent Pharmacokineticist as early as possible.
  - QC-cleared data only; start of review earliest if analyses of ~50 % of subjects are completed.
    - Consistency within subjects!
    - Pre-dose concentrations?
    - Rising values in the terminal phase?
    - Fluctuating values at  $C_{max}$ ?
    - Re-analysis ('pharmacokinetic repeats'): values confirmed/rejected?



# Case Study



subject	time [h]	analyte [ng/mL]	$\gamma$ -GT [U/L]	albumine [g/dL]
001	4.0	2.572	13	3.8
001	4.5	6.330	9	3.5
001	5.0	2.615	14	3.9
002	4.0	6.956	9	3.4
002	4.5	2.561	14	4.0
002	5.0	9.262	8	3.4

# In-Study Validation

- Repeated samples
  - SOP or guideline including acceptance criteria must be established explaining the reasons for repeating sample analysis.

Reasons for repeat analyses could include:

- repeat analysis of clinical or preclinical samples for regulatory purposes
- inconsistent replicate analysis
- samples outside of the assay range
- sample processing errors
- equipment failure
- poor chromatography
- inconsistent pharmacokinetic data

# In-Study Validation

- Repeated samples (cont.'d)
  - Reassays should be done in triplicate if sample volume allows.  
The rationale for the repeat analysis and the reporting of the repeat analysis should be clearly documented.
  - Currently no specific guidelines, but all repeated samples must be reported (original value, repeated value(s), used value, justification):
    - EU (Day 80 Critical Assessment Report, Generic medicinal product, 2006):  
[http://www.emea.europa.eu/pdfs/human/chmptemplates/D80\\_AR\\_Generics\\_Non-Clinical\\_Clinical\\_Guidance.pdf](http://www.emea.europa.eu/pdfs/human/chmptemplates/D80_AR_Generics_Non-Clinical_Clinical_Guidance.pdf)  
Reasons for any reanalysis of samples and if the final value has been decided correctly according to the relevant SOP.

# In-Study Validation

- Repeated samples (cont.'d)
  - FAD/CDER/OGD (Jan 2007):  
[http://www.fda.gov/Cder/ogd/DBE\\_tables.doc](http://www.fda.gov/Cder/ogd/DBE_tables.doc)


<b>Table 9 Reanalysis of Study Samples</b>								
Study No.								
Additional information in Volume(s), Page(s)								
Reason why assay was repeated	Number of samples reanalyzed				Number of recalculated values used after reanalysis			
	Actual number		% of total assays		Actual number		% of total assays	
	T	R	T	R	T	R	T	R
Pharmacokinetic <sup>1</sup>								
Reason A (e.g. below LOQ)								
Reason B								
Reason C								
Etc.								
Total								

1 - If no repeats were performed for pharmacokinetic reasons, insert "0.0."


Please provide a separate table for each analyte measured for each in-vivo study.

# Cross-Validation


- Comparison of validation parameters when  $\geq 2$  bio-analytical methods are used to generate data within the same study or across different studies. Example: an original validated bioanalytical method serves as the *reference* and a revised bioanalytical method is the *comparator*.
- Cross-validation should also be considered when data generated using different analytical techniques (e.g., LC/MS-MS vs. ELISA) in different studies are included in a regulatory submission.
- No specific recommendations in Arlington III WP.




# Case Study




Identical LLOQ,  
but bias in  
lower  
concentration  
range?



# Case Study



Bias in lower concentration range!



# Reporting Results


- Discrepancies between electronic data and paper reports.
  - Problems arise if electronic data in full precision are transferred to the statistical database.
  - Generally (paper-)reports contain only modified results (rounded to decimal places or significant figures, or – even worse – truncated values).
  - If PK-parameters have to be re-calculated from the paper-version or a PDF-file (*i.e.*, during an inspection), results may differ from the ones reported...

# Reporting Results

- Reasons for rounding of analytical data:
  - Pragmatic: avoid discrepancies between paper and electronic data which may raise unnecessary questions.
  - Scientific: use of full precision data implies a degree of accuracy/precision which is illusionary.

Raw data	3 decimal places	3 significant figures
31.41592653589793	31.416	31.4
3.14159265358979	3.142	3.14
0.31415926535898	0.314	0.314

Rounding to three decimal places is suggesting an ability to distinguish between 31.4154 and 31.4165 – a difference of 0.0035 % from the reported value!



# Reporting Results

- Personal opinion:
  - Most analysts have digested Arlington Conferences I-III and are familiar with 15 % accuracy / precision (20 % at LLOQ), but routinely come up with results like **3.141592653589793.\***)
  - Subconsciously they *believe*, that such a result is more correct than **3.14**.
  - If suggesting next time they should come up with **3.14159265358979323846264338327950288**, they tell me, that I am a funny person...

\*) at 15 % CV: 95 % Confidence Interval [2.21 – 4.07]  
at 5 % CV: 95 % Confidence Interval [2.83 – 3.45]

# Open Issue

**I have no opinion about ‘*incurred samples*’ – an expression which has no easily understandable meaning for me in the English language. *Nick Holford***

<http://www.boomer.org/pkin/PK07/PK2007010.html>

# Open Issue

- Incurred Sample Re-Analysis (Arlington III)
  - Situations, where standards and QCs may not adequately mimic that of study samples from dosed subjects.
    - Metabolites converting to parent compound,
    - Proteinbinding differences in patient samples,
    - Recovery issues,
    - Sample inhomogeneity,
    - Mass spectrometric ionization matrix effects.
  - It is generally accepted that the chance of incurred sample variability is greater in humans than in animals, so the following discussion pertains primarily to clinical studies.
    - Final decision as to the extent and nature of the incurred sample testing is left to the analytical investigator, and should be based on an in-depth understanding of the method, the behavior of the drug, metabolites, and any concomitant medications in the matrices of interest.

# Open Issue

- Incurred Sample Re-Analysis (cont.'d)
  - Considerations in selecting samples to be reassayed:
    - concentration,
    - patient population, and
    - special populations (e.g., renally impaired),
    - depending on what is known
      - about the drug,
      - its metabolism,
      - and its clearance.
  - Examples of studies that should be considered for incurred-sample concentration verification are
    - First-in-human,
    - Proof-of-concept in patients,
    - Special population, and
    - Bioequivalence (!) studies.

# Open Issue

- Incurred Sample Re-Analysis (cont.'d)
  - Re-assay of 15 % of samples was required in Canada since 1992, but was removed in Sep 2003.
  - Health Canada on 09 Jan 2008 published a 'Notice: Replication of Incurred Samples in Bioavailability/Bioequivalence Studies':
    - '[...] a voluntary submission of data collected on replicate samples since 2000. [...] This information will be used for research purposes only and will in no way affect past regulatory decisions. [...] Release of the information will be limited to summary statistics, with no linkage between the sponsor and the data.'
    - HPB hopes '... to be able to present our findings at the next Canadian Workshop on Recent Issues in GLP Bioanalysis on April 17-18, 2008 in Montreal.'

[http://www.hc-sc.gc.ca/dhp-mps/alt\\_formats/hpfb-dgpsa/pdf/prodpharma/notice\\_bioan\\_avis\\_anbio\\_e.pdf](http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/notice_bioan_avis_anbio_e.pdf)

# Open Issue

- Incurred Sample Re-Analysis (cont.'d)
  - European Initiative started by the 'European Bioanalysis Forum':  
<http://www.aapspharmaceutica.com/meetings/files/112/PhilipTimmermanebfperspective.pdf>  
Until now only open to the industry, but collaboration planned with other scientific and interprofessional groups on BA related topics (academia, vendors, CROs, or regulatory bodies)...
  - AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples Samples – Implications of Crystal City Recommendations (Feb 2008)  
<http://www.aapspharmaceutica.org/meetings/meeting.asp?id=112>  
<http://www.aapspharmaceutica.org/GLP/>

## ...to be remembered


**Whenever a theory appears to you as the only possible one, take this as a sign that you have neither understood the theory nor the problem which it was intended to solve.**

*Karl R. Popper*

**Even though it's applied science we're dealin' with, it still is – *science!***

*Leslie Z. Benet*

# Conclusions, Outlook



"Wait! Wait! Listen to me! ...  
We don't HAVE to be just sheep!"

- David Bourne's (Uni. Oklahoma) e-mail list
  - A rather active list (3200+ members, about 50 postings/week) covering almost any aspect of PK/PD/bio-analytics...
    - Subscription  
<http://www.boomer.org/pkin/>
    - Search page  
<http://www.boomer.org/pkin/simple.html>
- BA and BE Forum (BEBAC Vienna)
  - Specialized in BA/BE/bioanalytics.
    - No registration necessary to *read* postings.  
<http://forum.bebac.at/>
    - Registration (to post own questions)  
<http://forum.bebac.at/register.php>

**Is your BA/BE study  
bioanalytically  
compliant?  
*Köszönöm szépen!***

Helmut Schütz

**BEBAC**

Consultancy Services for  
Bioequivalence and Bioavailability Studies  
1070 Vienna, Austria  
[helmut.schuetz@bebac.at](mailto:helmut.schuetz@bebac.at)

# References

- ICH
  - Q2A: Validation of Analytical Methods: Definitions and Terminology (1994)
  - Q2B: Validation of Analytical Methods: Methodology. (1996)
- OECD
  - OECD Environmental Health and Safety Publications, Series on Principles of Good Laboratory Practice and Compliance Monitoring (1995-2002)
- WHO
  - Handbook for GLP (2001)
  - Fortieth Report - TRS No. 937 (2006)
    - Annex 7: Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability
    - Annex 9: Additional guidance for organizations performing *in vivo* bioequivalence studies
- US-FDA
  - Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) Guidance for Industry. Bioanalytical Method Validation. (May 2001)
- Collection of links to global documents  
<http://bebac.at/Guidelines.htm>
- Brazilian Sanitary Surveillance Agency (ANVISA)
  - Manual for Good Bioavailability and Bioequivalence Studies.  
Volume 1, Module 2: Analytical Step  
<https://www.anvisa.gov.br/eng/bio/manual/volume1.zip>  
Brasília (2000)

# References

- Pachla, L.A., Wright, D.S., and D.L. Reynolds  
 Bioanalytical Considerations for Pharmacokinetic and Biopharmaceutic Studies  
 J Clin Pharmacol 21, 332-335 (1981)
- Cartwright, A.C. *et al.*;  
 International harmonization and consensus DIA meeting on bioavailability and bioequivalence testing requirements and standards  
 Drug Information Journal 25, 471 (1991)
- Karnes, S.T., Shiu, G., and V.P. Shah;  
 Validation of Bioanalytical Methods  
 Pharm Res 8, 421-421 (1991)
- DeSilva, B. *et al.*;  
 Recommendations for the Bioanalytical Method Validation of Ligand-binding Assays to Support Pharmacokinetic Assessments of Macromolecules  
 Pharm Res 20, 1885-1990 (2003)
- Shah, V.P. *et al.*;  
 Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies  
 Int J Pharm 82, 1-7 (1992)  
 → 'Arlington I' (Dec 3-5, 1990)
- Shah, V.P., *et al.*;  
 Bioanalytical Method Validation—A Revisit with a Decade of Progress  
 Pharm Res 17, 1551-1557 (2000)  
 → 'Arlington II' (Jan 12-14, 2000)
- Viswanathan, C.T., *et al.*;  
 Workshop/Conference Report—Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays  
 The AAPS Journal 9(1) Article 4, E30-E41 (2007)  
<http://www.aapsi.org/articles/aapsi0901/aapsi0901004/aapsi0901004.pdf>  
 → 'Arlington III' (May 1-3, 2006)
- J.W.A. Findlay and R. Dillard;  
 Appropriate Calibration Curve Fitting in Ligand Binding Assays  
 The AAPS Journal 9(2) Article 29, E260-E267 (2007)  
<http://www.aapsi.org/articles/aapsi0902/aapsi0902029/aapsi0902029.pdf>

# Routine Drug Analysis Process and Run Acceptance Criteria (Arlington III WP)

Process or Criteria	Chromatographic Assays	Ligand-Binding Assays
Preparation of standards and QC samples	Standards and QC samples can be prepared from the same spiking stock solution, provided the solution stability and accuracy have been verified. A single source of matrix may also be used, provided selectivity has been verified.	
Placement of samples	Standard curve samples, blanks, QCs, and study samples can be arranged as considered appropriate within the run, and support detection of assay drift over the run.	
Number of calibration standards in a run	Include with each analytical batch: <ul style="list-style-type: none"> <li>▪ Blank matrix (sample without IS)</li> <li>▪ Zero standard (matrix sample with IS)</li> <li>▪ Non-zero calibration standards: <math>\geq 6</math> standard points</li> </ul>	Include with each analytical batch or micro-titer plate: <ul style="list-style-type: none"> <li>▪ Blank matrix</li> <li>▪ Non-zero calibration standards: <math>\geq 6</math> standard points. Can include anchor points (below LLOQ or above ULOQ in the asymptotic low- and high-concentration end of the standard curve)</li> </ul>

# Routine Drug Analysis Process and Run Acceptance Criteria (Arlington III WP)

Process or Criteria	Chromatographic Assays	Ligand-Binding Assays
Acceptance criteria for calibration standards	Residuals (absolute difference between the back calculated and nominal concentration) for each calibration standard should meet the following limits: <ul style="list-style-type: none"> <li>▪ LLOQ standard &lt;20 %</li> <li>▪ All other standards &lt;15 %</li> </ul>	Residuals for each calibration standard should meet the following limits: <ul style="list-style-type: none"> <li>▪ LLOQ and ULOQ standards &lt;25 %</li> <li>▪ All other standards &lt;20 %</li> <li>▪ Any anchor points if used, are not to be included in the above acceptance criteria.</li> </ul>
	A minimum of 75 % standards (at least 6 nonzero points) should be within the above limits for the analytical run to qualify. Values falling outside these limits can be discarded, provided they do not change the established model.	

# Routine Drug Analysis Process and Run Acceptance Criteria (Arlington III WP)

Process or Criteria	Chromatographic Assays	Ligand-Binding Assays
Number of QC samples in a batch	<p>Include QC samples at the following 3 concentrations (within the calibration range) in duplicate with each analytical batch:</p> <ul style="list-style-type: none"> <li>▪ Low: near the LLOQ (up to 3x LLOQ)</li> <li>▪ Medium: midrange of calibration curve</li> <li>▪ High: near the high end of range</li> </ul>	<p>QC samples at the following 3 concentrations (within the calibration range) in duplicate should be added to each micro-titer plate:</p> <ul style="list-style-type: none"> <li>▪ Low: above the second non-anchor standard, ~3x LLOQ</li> <li>▪ Medium: midrange of calibration curve</li> <li>▪ High: below the second non-anchor point high standard at ~75 % of ULOQ</li> </ul>
<p>Each analytical batch should contain 6 or a minimum of 5 % of the total number of unknown samples. Add QCs in multiples of three concentrations (low, medium, high) when needed.</p>		

# Routine Drug Analysis Process and Run Acceptance Criteria (Arlington III WP)

Process or Criteria	Chromatographic Assays	Ligand-Binding Assays
Acceptance criteria for QC samples	<p>Allowed % deviation from nominal values:</p> <ul style="list-style-type: none"> <li>▪ QCs prepared at all concentrations greater than LLOQ &lt;15 %</li> <li>▪ Low QC (if prepared at LLOQ) &lt;20 %</li> </ul>	<p>Allowed % deviation from nominal values:</p> <ul style="list-style-type: none"> <li>▪ QCs prepared at all concentrations other than LLOQ and ULOQ &lt;20 %</li> <li>▪ Low and high QC (if prepared at LLOQ or ULOQ) &lt;25 %</li> <li>▪ In certain situations wider acceptance criteria may be justified, e.g., when total error during assay validation approaches 30 %</li> </ul>
<p>At least 67 % (4 of 6) of the QC samples should be within the above limits; 33 % of the QC samples (not all replicates at the same concentration) can be outside the limits. If there are more than 2 QC samples at a concentration, then 50% of QC samples at each concentration should pass the above limits of deviation.</p>		

# Routine Drug Analysis Process and Run Acceptance Criteria (Arlington III WP)

Process or Criteria	Chromatographic Assays	Ligand-Binding Assays
Replicate analysis	In general, samples can be analyzed with a single determination without replicate analysis if the assay method has acceptable variability as defined by the validation data. Duplicate or replicate analysis can be performed for a difficult procedure where high precision and accuracy may be difficult to obtain.	Accuracy can generally be improved by replicate analysis. Therefore, duplicate analysis is recommended. If replicate analysis is performed, the same procedure should be used for samples and standards.
Multiple analytes in a run	Samples involving multiple analytes in a run should not be rejected based on the data from 1 analyte failing the acceptance criteria.	
Rejected runs	The data from rejected runs need not be documented, but the fact that a run was rejected and the reason for failure should be reported.	